Immune system

Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

Tuesday, April 13, 2021 - 7:55am

b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.

Key Points: 
  • b'CAMBRIDGE, Mass., SUZHOU, China andROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company,presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research Annual Meeting.
  • This meeting is being held virtually from April 10-15, 2021.
  • The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM\'s proprietary H2L2 Harbour Mice platform.\nBy leveraging its innovative discovery engine based on the Harbour Mice antibody platforms, HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology.
  • Following the previously reported monoclonal antibody against a novel target CCR8, HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint - B7H7.

Allergy & Asthma Network Launches First Nationwide Asthma Awareness Month Virtual Fitness Challenge

Monday, April 12, 2021 - 6:33pm

b"VIENNA, Va., April 12, 2021 /PRNewswire/ -- This May, Allergy & Asthma Network will celebrate Asthma Awareness Month with its first-ever Virtual Fitness Challenge.

Key Points: 
  • b"VIENNA, Va., April 12, 2021 /PRNewswire/ -- This May, Allergy & Asthma Network will celebrate Asthma Awareness Month with its first-ever Virtual Fitness Challenge.
  • The month-long initiative encourages people to get active and live healthier while supporting Allergy & Asthma Network.
  • All proceeds will go to the Network's outreach, education, advocacy and research programs.\nAllergy & Asthma Network is teaming up with Virginia-based certified personal trainer Shannon Simpson to develop the online fitness program.
  • Health benefits include:\nRegistration for the Virtual Fitness Challenge is $20.00.

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Saturday, April 10, 2021 - 1:30pm

The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.

Key Points: 
  • The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.
  • "We are pleased to announce new in vivo data today that show INTASYL mPH-762 offered strong tumor control in Hepa 1-6 and CT26 models, which are PD-1 responsive and PD-1 refractory models, respectively.
  • "These data further support our excitement around this asset andto bring PH-762 to patients, starting with our first clinical study later this year."
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function

Saturday, April 10, 2021 - 1:31pm

The data demonstrated that CD70 knockout performed better than other checkpoint genes and provided advantages for CAR-T cells targeting multiple antigens beyond CD70.

Key Points: 
  • The data demonstrated that CD70 knockout performed better than other checkpoint genes and provided advantages for CAR-T cells targeting multiple antigens beyond CD70.
  • In contrast, CAR-T cells with classical checkpoint genes knocked out showed no improved properties and often proved detrimental to CAR-T function.
  • CRISPR Therapeutics is currently studying CTX130TM, an investigational allogeneic CAR-T cell therapy, in patients with CD70-expressing tumors, including clear cell renal cell carcinoma and B and T cell malignancies.
  • CRISPR THERAPEUTICS word mark and design logo and CTX130TM are trademarks and registered trademarks of CRISPR Therapeutics AG.

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

Saturday, April 10, 2021 - 1:31pm

The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.

Key Points: 
  • The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.
  • As we are still exploring optimal dosing, these early responses are particularly encouraging, said Joern Aldag, Chief Executive Officer of HOOKIPA.
  • Preliminary data showed a strong antigen-specific T cell response after one dose of HB-201 or HB-202, based on direct Enzyme-Linked ImmunoSpot (ELISpot) T cell analysis.
  • Other preliminary immunogenicity data highlight immune system activation following a single dose of HB-201.

Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting

Saturday, April 10, 2021 - 1:30pm

Allogenes internally-developed TurboCAR technology platform is capable of delivering cytokine activation signaling selectively to CAR T cells.

Key Points: 
  • Allogenes internally-developed TurboCAR technology platform is capable of delivering cytokine activation signaling selectively to CAR T cells.
  • We are very excited about the potential to expand our TurboCAR technology platform to maximize its impact in allogeneic cell therapy.
  • Allogene Therapeutics, with headquarters inSouth San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer.
  • AlloCAR, AlloCAR T and TurboCAR are trademarks of Allogene Therapeutics, Inc.

New Clinical Responses for AGEN1181 Presented at AACR

Saturday, April 10, 2021 - 1:35pm

AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.

Key Points: 
  • AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.
  • In two separate presentations at AACR, Agenus showcased the optimal performance of AGEN1181 in relevant models.
  • In addition, as the clinical data matures, additional responses as well as a conversion from a partial response to a complete response, have been observed.
  • The new data announced today include the following clinical responses:
    E-poster presentations were made available on the conference platform on April 10 at 8:30am ET.

Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

Saturday, April 10, 2021 - 1:30pm

The data from this case study show a polyclonal response and demonstrate our ability to establish product specificity, polyclonal reactivities, monitor persistence and expansion, as well as derive associations to efficacy.

Key Points: 
  • The data from this case study show a polyclonal response and demonstrate our ability to establish product specificity, polyclonal reactivities, monitor persistence and expansion, as well as derive associations to efficacy.
  • These are important differentiators of our technology that provide a mechanistic understanding of TIL therapy and potentially lend themselves to a reproducible potency assay.
  • In 2020, the patient had a recurrent lesion excised and cNeT manufactured through the VELOSTM process.
  • Up to 53% of the T cells in the manufactured product were reactive to the patients own clonal neoantigens following stimulation.

Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

Saturday, April 10, 2021 - 1:31pm

The translational analyses presented at AACR link JTX-8064s mechanism to tumor types that may respond better to LILRB2 inhibition, saidElizabeth Trehu, M.D., chief medical officer ofJounce Therapeutics.

Key Points: 
  • The translational analyses presented at AACR link JTX-8064s mechanism to tumor types that may respond better to LILRB2 inhibition, saidElizabeth Trehu, M.D., chief medical officer ofJounce Therapeutics.
  • Preclinical data presented at the 2020 Society for Immunotherapyof Cancers Annual Meeting and the 2019and 2021 American Association for Cancer ResearchAnnual Meetings support the development of JTX-8064 as a novel immunotherapy to reprogram immune-suppressive macrophages and enhance anti-tumor immunity.
  • Jounces highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting

Saturday, April 10, 2021 - 1:31pm

In addition, preclinical data from the Companys autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR.

Key Points: 
  • In addition, preclinical data from the Companys autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR.
  • Translational data highlights from the poster include:
    CD4:CD8 Ratio: The median CD4:CD8 ratio in the gavo-cel T cell products was 7.15.
  • We look forward to providing further updates on our solid tumor pipeline throughout the year.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.